Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Jan 13, 2020- New clinical trial will assess first-of-its-kind MitraClip™ transcatheter mitral valve repair against current standard of care surgery in a new, expanded patient population- If successful, the REPAIR MR study has potential to expand MitraClip's current indication (patients at prohibitive risk for surgery) to also include patients at moderate risk- Jan 7, 2020- For people battling advanced heart failure, Abbott's HeartMate 3 heart pump can now be implanted through an incision in the chest wall versus open heart surgery- New, less invasive technique provides cardiac surgeons with the ability to choose the optimal surgical method for their patients
Nov 13, 2019- Mr. White will remain Executive Chairman of the Board- Mr. Ford has been elected to the Abbott Board- Nov 6, 2019- Discovery marks the first time a new subtype of HIV-1 has been identified since 2000- Abbott is making this new strain accessible to the research community to evaluate its impact to diagnostic testing, treatments and potential vaccines
-
Oct 22, 2019- One-third of Americans have heard someone say: "I drive better when I've smoked marijuana"- While drunk driving is on the decline, drug-impaired driving is on the rise[1]- Eleven states and Washington, DC, have legalized marijuana for recreational use; Illinois, Michigan are two of the next states to begin adult-use sales in 2020
- Oct 21, 2019Abbott and the Australian Red Cross Blood Service extend 30-year partnership of providing safe, life-saving blood supply in Australia
- Oct 16, 2019- Third-quarter sales growth of 5.5 percent; organic sales growth of 7.6 percent- Exceptional growth across key platforms of FreeStyle Libre, MitraClip and Alinity- Continues to strengthen portfolio with a steady cadence of new product approvals, reimbursement coverage and clinical data
- Oct 15, 2019- Companies aim to integrate Abbott's FreeStyle Libre glucose sensing technology with Tandem's insulin delivery products to expand choices for people with diabetes
-
Oct 15, 2019-- Oct. 17, 2019, marks the one-year anniversary of legalized recreational cannabis nationwide-- A year after legalization, 71% of Canadians are concerned about its impact on road safety-- Survey shows Canadians want more to be done to keep roads safe
Oct 14, 2019- Collaboration combines Abbott′s world-leading glucose sensing technology with Omada Health's best-in-class, proprietary digital coaching platform to provide personalized, on-the-go care- As part of Omada's expanded Type 2 diabetes offering, FreeStyle Libre will be the exclusive CGM delivered directly to participants' doorsteps - expanding access to the technology for more people with diabetes-
Oct 7, 2019- Abbott volunteers work with teachers to empower students to take charge of their health, adopting healthy habits that last a lifetime- Initiative aims to inspire kids to take steps today to prevent chronic diseases tomorrow
- Sep 29, 2019- New late-breaking data at TCT 2019 demonstrate that Abbott's MitraClip™ is cost-effective for heart failure patients with significant secondary mitral regurgitation compared to guideline-directed medical therapy alone- Data analyses presented at TCT demonstrated that over the lifetime of a typical COAPT patient, MitraClip showed improvements in both projected life expectancy and quality of life, and that those benefits are sustained through three years
- Sep 28, 2019- New data presented at TCT 2019 on Abbott's TriClip device from the TRILUMINATE Feasibility Study met both the primary safety and performance endpoints- Abbott's TriClip tricuspid valve repair system design is based on the company's market-leading MitraClip™ technology
- Sep 26, 2019- Proclaim™ XR neurostimulation system uses Abbott's proprietary, low energy BurstDR™ therapy coupled with the BoldXR™ low dosing protocol for safe, effective pain relief and a battery that lasts up to 10 Years*- More than 50 million people in the United States are affected by chronic pain- Abbott's low-dose and low-energy pain management technology is designed to provide pain relief and improve system longevity, offering patients a life-altering option for pain relief without the hassles of recharging
- Sep 25, 2019Newly cleared diagnostic test could help identify heart attacks several hours sooner than standard troponin tests and help improve diagnosis in women
- Sep 17, 2019- World's smallest pediatric treatments pioneered by Abbott address critical needs for the most vulnerable patients: babies and children born with common congenital heart defects- Includes pediatric mechanical heart valve and first minimally invasive device to treat premature babies and newborns born with an opening in their heart
- Sep 16, 2019- Abbott achieves top scores across all three key areas of economic, social and environmental performance, earns more than double the average score in Health Care Equipment & Supplies industry sector- Company's longstanding commitment to sustainability demonstrated by inclusion on DJSI for 15 consecutive years
- Sep 16, 2019- Collaboration aims to provide a connected device experience for millions of people living with diabetes using insulin- Two world leaders in diabetes work together to drive meaningful change in care
- Sep 10, 2019- New research found Abbott's algorithm created through machine learning could give doctors a more individualized calculation, leveraging factors such as age, sex and the changing dynamics of troponin protein levels in the blood, to improve heart attack diagnosis- This technology is the first machine learning developed algorithm that combines high sensitive troponin testing with other patient details to help doctors better determine if a heart attack is occurring
- Sep 9, 2019- New initiative will provide vital primary care services within a 30-minute walk of all Rwandans' homes- Health post workers will test and treat pregnant women for multiple infectious diseases that can have serious health consequences for both mothers and newborns if not diagnosed and treated early